20348-17-8

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-3-HYDROXY-5-PICOLINE is used as a building block for the synthesis of various drugs and materials, leveraging its unique chemical properties to create novel therapeutic agents.
Used in Chemical Industry:
In the chemical industry, 2-AMINO-3-HYDROXY-5-PICOLINE serves as a key intermediate in the production of specialty chemicals and materials, contributing to the development of innovative products.
Used in Neurological and Psychiatric Applications:
2-AMINO-3-HYDROXY-5-PICOLINE is studied for its potential therapeutic effects in neurological and psychiatric disorders, given its involvement in the biosynthesis of serotonin, a neurotransmitter with significant implications for mood regulation and cognitive function. Its role in NAD+ formation may also contribute to its therapeutic potential, as NAD+ is implicated in various cellular processes related to health and disease.

InChI:InChI=1/C6H8N2O/c1-4-2-5(9)6(7)8-3-4/h2-3,9H,1H3,(H2,7,8)

Upstream product

• 17282-00-7 3-bromo-5-methylpyridin-2-amine 
• 42732-49-0 5-methyl-3-pyridinol 
• 15128-88-8 5-methyl-2-nitropyridin-3-ol 

Relevant academic research and scientific papers

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazolpyridines and Analogues

The search for a successor to 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazopyridine, Sch 28080 (27), a compound that exhibits gastric antisecretory and cytoprotective properties and has undergone clinical evaluation as an antiulcer agent, has culminated in the identification of four related compounds that exhibit pharmacologic profiles similar to that of 27.In three of these potential successors an amino group functions as a surrogate for the 3-cyanomethyl substituent of the prototype.The present work concerns, in addition to an evaluation of the structure-activity relationships of a series of analogues of 27, preliminary studies of the pharmacodynamics and metabolism of 27, performed with the aid of cyano carbon labeled versions of the drug (13C labeled; 28; 14C labeled, 29).These studies have shown that 27 is well-absorbed and extensively metabolized and that the major metabolite of 27 is the thiocyanate anion.A similar study performed on 3-amino-2-methyl-8-(phenylmethoxy)imidazopyridine, labeled at the 3-position with carbon-13 (41) or carbon-14 (42), revealed that this compound, which has an antisecretory/cytoprotective profile comparable to that of 27, is also metabolized to thiocyanate anion, although this must occur via a different mechanism.The chemistry section includes a discussion of the potential sites of protonation of the pharmacologically similar 3-amino analogue 40 and the structurally related imidazopyrazine 67.Predictions based on charge density and protonation product stabilities are presented.That N1 is the site of protonation in these analogues has been definitively demonstrated by X-ray crystal structure analysis, which alsounequivocally established the assigned imidazopyrazine ring structure.

CNS active compounds

Compounds of the formula STR1 wherein R may be hydrogen or a straight or branched chain alkyl radical of from 1 to 10 carbon atoms, aryl of from 6 to 10 carbon atoms, or aralkyl of from 7 to 10 carbon atoms; Y may be hydrogen, alkyl of from 1 to 4 carbons, CF3, F, Cl, or Br; and Z may be hydrogen or as defined hereinafter. These compounds are useful as central nervous system stimulants or more specifically in enhancing performance or as mood elevators.